Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00562887 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
A Phase 2 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
NCT00562887 is a Phase 2 study that was terminated before completion, run by Abbott. The registered enrollment target is 246 participants.
The verdict
NCT00562887, a Phase 2 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
Study Summary
To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ABT-874
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00562887
The ClinicalTrials.gov registry entry for NCT00562887 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00562887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00562887 about?
NCT00562887 is a clinical study titled "Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease". To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.
What is the current status of trial NCT00562887?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2007-11.
What interventions are being tested in trial NCT00562887?
The interventions under investigation include: Placebo (BIOLOGICAL), ABT-874 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00562887?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.